Login / Signup

Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.

Naseema GangatErika MorsiaJames M ForanJeanne M PalmerMichelle A ElliottAyalew Tefferi
Published in: British journal of haematology (2020)
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • low grade
  • patient reported outcomes
  • high grade
  • chronic lymphocytic leukemia